Agenus Inc. Secures $340 Million in Oversubscribed Private Placement to Propel Oncology Research

Agenus has entered into a securities purchase agreement that will initially yield approximately $85 million in upfront gross proceeds, with the potential for an additional $255 million through the full exercise of purchase warrants. The financing round was led by Commodore Capital, alongside notable participants such as RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals.

The company plans to close the private placement on or around July 15, 2026, pending customary closing conditions. The share and warrant pricing is set at a premium compared to the market closing price as of July 10, 2026.

The net proceeds from this financing will primarily support Agenus’ strategic focus on the neoadjuvant treatment of MSS colon cancer, particularly through the advancement of the ROBBIN1 trial. This trial is designed to assess the efficacy of the combination of botensilimab (BOT) and balstilimab (BAL) in high-risk Stage II and Stage III MSS colon cancer. With approximately 38,000 new cases reported annually in the U.S. alone, the potential market for effective therapies is substantial, estimated at over $7 billion.

The preliminary results from Agenus’ Phase 2 studies, NEST and UNICORN, have shown promising outcomes in patients treated with BOT+BAL. Approximately 60-70% of patients exhibited deep, durable responses, with major pathologic response rates between 35-40% and pathologic complete response in about 30%. These findings suggest that the BOT+BAL regimen may significantly improve event-free survival in patients, making it a critical area of focus for the company.

Dr. Steven O'Day, Chief Medical Officer at Agenus, emphasized the unique opportunity presented by the ROBBIN trial, stating, "Our plan to prioritize neoadjuvant BOT+BAL in MSS colon cancer reflects both the strength of the emerging clinical evidence and the opportunity to bring this important combination regimen to patients where it may have the greatest impact."

In line with this strategic shift, Agenus announced it will discontinue financial support for its ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer. This decision allows the company to concentrate its resources on the more promising neoadjuvant approach with BOT+BAL, while ensuring continued support for current patients in the BATTMAN study.

The company has set ambitious timelines for the ROBBIN trial, with the first patient expected to be dosed in Q1 of 2027. Additional interim analyses are scheduled for the second half of 2027 and 2029, with final event-free survival results anticipated in the second half of 2030.

Garo H. Armen, Ph.D., Founder and CEO of Agenus, stated, "Since Agenus was founded 32 years ago, our mission has been to harness the immune system to improve outcomes and, where possible, cure cancer. The ROBBIN trial is designed to confirm the rapid and deep activity observed across the NEST and UNICORN trials."

With the successful completion of this private placement, Agenus is well-positioned to advance its research and development efforts in the field of immuno-oncology. The company’s commitment to addressing the significant unmet need in MSS colon cancer, combined with its innovative BOT+BAL treatment, could pave the way for transformative changes in patient care.

As Agenus embarks on this critical phase of its development, the financial and medical communities will be closely monitoring its progress, particularly with the ROBBIN trial set to generate pivotal data in the coming years.